Embolic Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 90.62%
- Profit Growth 33.73%
- Ebitda 196.59%
- Net Worth 67.81%
- Total Assets 20.07%
About Embolic Biotech
Embolic Biotech Private Limited (EBPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 May 2019 (Five years and nine months 23 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Meenu Srivastava and Kiran Singh serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110MH2019PTC324996
- Company No.
324996
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Embolic Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meenu Srivastava  | Director | 06-May-2019 | Current |
| Kiran Singh | Director | 06-May-2019 | Current |
Financial Performance of Embolic Biotech.
Embolic Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 90.62% increase. The company also saw a substantial improvement in profitability, with a 33.73% increase in profit. The company's net worth Soared by an impressive increase of 67.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Embolic Biotech?
In 2022, Embolic Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Embolic Biotech?
Embolic Biotech has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Embolic Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Embolic Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.